Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Bryan Clines

Bryan Clines

Regulatory Coordinator III

Cancer Center Division

Collaboration(14)

Michael Grandner
Rachna Shroff
Hina Arif Tiwari
Edward Gelmann
Bital Savir-Baruch

Page 1 of 3

Grants(6)

A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Active·2024·$0 / $2.2M·
External
prostate cancer, clinical trial, treatment comparison, metastatic cancer, hormone therapy
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
Active·2024·$0 / $625.4K·
External
oncology, clinical trial, drug combination, efficacy, patient safety
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active·2023·$0 / $684.8K·
External
cancer treatment, drug trial, dose escalation, solid tumors, lymphomas
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Active·2023·$0 / $494.2K·
External
cancer, immunotherapy, clinical trials, metastasis, treatment comparison
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
Active·2023·$0 / $432.5K·
External
gsk-3b inhibitor, hematologic malignancies, chemotherapy

Page 1 of 2